Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09GFL
|
||||
| Former ID |
DAP001122
|
||||
| Drug Name |
Trihexyphenidyl
|
||||
| Synonyms |
Benzhexol; Benzhexolum; Trihexane; Trihexifenidilo; Trihexy; Trihexylphenidyl; Trihexylphenidyle; Trihexylphenizyl; Trihexyphenidyle; Trihexyphenidylum; Triphenidyl; Artane Sequels; PMS Trihexyphenidyl; Parkinane retard; Apo-Trihex; Artane (TN); Sedrena (free base); Trihexifenidilo [INN-Spanish]; Trihexyphenidyl (INN); Trihexyphenidyl [INN:BAN]; Trihexyphenidyle [INN-French]; Trihexyphenidylum [INN-Latin]; Apo-Trihex (TN); Apo-trihex (TN); 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease; Dystonia [ICD9: 332; ICD10:G20, G24] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antiparkinson Agents
|
||||
| Company |
Lederle Laboratories Div American Cyanamid Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H31NO
|
||||
| InChI |
InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
|
||||
| InChIKey |
HWHLPVGTWGOCJO-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 144-11-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9380, 76985, 5664292, 7978767, 8153428, 10508113, 11335547, 11360786, 11363526, 11366088, 11368650, 11372249, 11373976, 11376812, 11461758, 11466729, 11467849, 11484493, 11486538, 11488645, 11491190, 11492184, 11494446, 14751778, 29224611, 46507717, 47365113, 47515241, 47515242, 47662205, 47662206, 47662207, 47736399, 48110381, 48259153, 48416664, 49698895, 50016994, 50105266, 50483190, 57322850, 85209532, 85788388, 90341555, 96025321, 103555930, 104309620, 124750254, 124881579, 124881580
|
||||
| SuperDrug ATC ID |
N04AA01
|
||||
| SuperDrug CAS ID |
cas=000144116
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M1 | Target Info | Antagonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7315). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats. Psychopharmacology (Berl). 2009 Apr;203(2):295-301. Epub 2008 Aug 7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.